<?xml version='1.0' encoding='UTF-8'?>
<Organism_Record>
  <Organism_ID>ASD10820000_1</Organism_ID>
  <Organism>Human</Organism>
  <Organism_Latin>Homo sapiens</Organism_Latin>
  <UniProt_ID>Q15109</UniProt_ID>
  <Seq_Length>404</Seq_Length>
  <Molecule_Weight>42803</Molecule_Weight>
  <KEGG_ID>hsa:177</KEGG_ID>
  <EBI_ID>EBI-1646426</EBI_ID>
  <Function_Summary>Mediates interactions of advanced glycosylation end products (AGE). These are nonenzymatically glycosylated proteins which accumulate in vascular tissue in aging and at an accelerated rate in diabetes. Acts as a mediator of both acute and chronic vascular inflammation in conditions such as atherosclerosis and in particular as a complication of diabetes. AGE/RAGE signaling plays an important role in regulating the production/expression of TNF-alpha, oxidative stress, and endothelial dysfunction in type 2 diabetes. Interaction with S100A12 on endothelium, mononuclear phagocytes, and lymphocytes triggers cellular activation, with generation of key proinflammatory mediators. Interaction with S100B after myocardial infarction may play a role in myocyte apoptosis by activating ERK1/2 and p53/TP53 signaling (By similarity). Receptor for amyloid beta peptide. Contributes to the translocation of amyloid-beta peptide (ABPP) across the cell membrane from the extracellular to the intracellular space in cortical neurons. ABPP-initiated RAGE signaling, especially stimulation of p38 mitogen-activated protein kinase (MAPK), has the capacity to drive a transport system delivering ABPP as a complex with RAGE to the intraneuronal space. Can also bind oligonucleotides.</Function_Summary>
  <Pfam_ID>PF08205:C2-set_2</Pfam_ID>
  <Allosteric_Activator_Count>0</Allosteric_Activator_Count>
  <Allosteric_Inhibitor_Count>0</Allosteric_Inhibitor_Count>
  <Allosteric_Regulator_Count>0</Allosteric_Regulator_Count>
  <Alias_List>
      <Alias>Receptor for advanced glycosylation end products</Alias>
  </Alias_List>
  <Function_List>
    <Funtion>
      <Detail>Combining with an extracellular or intracellular signal and transmitting the signal from one side of the membrane to the other to initiate a change in cell activity.</Detail>
      <Keyword>Transmembrane receptor activity</Keyword>
      <Ontology_ID>GO:0004888</Ontology_ID>
    </Funtion>
  </Function_List>
  <Mutation_List>
    <Muntion>
      <Position>100</Position>
      <Original>Gln</Original>
      <Variation>Arg</Variation>
    </Muntion>
    <Muntion>
      <Position>82</Position>
      <Original>Gly</Original>
      <Variation>Ser</Variation>
    </Muntion>
  </Mutation_List>
  <BioProcess_List>
    <BioProcess>
      <Detail>The process whose specific outcome is the progression of a neuron projection over time, from its formation to the mature structure. A neuron projection is any process extending from a neural cell, such as axons or dendrites (collectively called neurites).</Detail>
      <Keyword>Neuron projection development</Keyword>
      <Ontology_ID>GO:0031175</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Innate immune responses are defense responses mediated by germline encoded components that directly recognize components of potential pathogens.</Detail>
      <Keyword>Innate immune response</Keyword>
      <Ontology_ID>GO:0045087</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>The immediate defensive reaction (by vertebrate tissue) to infection or injury caused by chemical or physical agents. The process is characterized by local vasodilation, extravasation of plasma into intercellular spaces and accumulation of white blood cells and macrophages.</Detail>
      <Keyword>Inflammatory response</Keyword>
      <Ontology_ID>GO:0006954</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that initiates the directed movement of a motile cell or organism towards a higher concentration in a concentration gradient of a specific chemical.</Detail>
      <Keyword>Induction of positive chemotaxis</Keyword>
      <Ontology_ID>GO:0050930</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any process that activates or increases the frequency, rate or extent of activity of the transcription factor NF-kappaB.</Detail>
      <Keyword>Positive regulation of NF-kappaB transcription factor activity</Keyword>
      <Ontology_ID>GO:0051092</Ontology_ID>
    </BioProcess>
    <BioProcess>
      <Detail>Any series of molecular signals initiated by the binding of an extracellular ligand to a receptor on the surface of the target cell.</Detail>
      <Keyword>Cell surface receptor linked signaling pathway</Keyword>
      <Ontology_ID>GO:0007166</Ontology_ID>
    </BioProcess>
  </BioProcess_List>
  <Molecule_Seq>
    <Protein_Seq>MAAGTAVGAWVLVLSLWGAVVGAQNITARIGEPLVLKCKGAPKKPPQRLEWKLNTGRTEAWKVLSPQGGGPWDSVARVLPNGSLFLPAVGIQDEGIFRCQAMNRNGKETKSNYRVRVYQIPGKPEIVDSASELTAGVPNKVGTCVSEGSYPAGTLSWHLDGKPLVPNEKGVSVKEQTRRHPETGLFTLQSELMVTPARGGDPRPTFSCSFSPGLPRHRALRTAPIQPRVWEPVPLEEVQLVVEPEGGAVAPGGTVTLTCEVPAQPSPQIHWMKDGVPLPLPPSPVLILPEIGPQDQGTYSCVATHSSHGPQESRAVSISIIEPGEEGPTAGSVGGSGLGTLALALGILGGLGTAALLIGVILWQRRQRRGEERKAPENQEEEEERAELNQSEEPEAGESSTGGP</Protein_Seq>
    <DNA_Seq>CTGAAAGATGGGGGCTGGAGAGAGGGTGCAGGCCCCACCTAGGGCGGAGGCCACAGCAGGGAGAGGGGCAGACAGAGCCAGGACCCTGGAAGGAAGCAGGATGGCAGCCGGAACAGCAGTTGGAGCCTGGGTGCTGGTCCTCAGTCTGTGGGGGGCAGTAGTAGGTGCTCAAAACATCACAGCCCGGATTGGCGAGCCACTGGTGCTGAAGTGTAAGGGGGCCCCCAAGAAACCACCCCAGCGGCTGGAATGGAAACTGAACACAGGCCGGACAGAAGCTTGGAAGGTCCTGTCTCCCCAGGGAGGAGGCCCCTGGGACAGTGTGGCTCGTGTCCTTCCCAACGGCTCCCTCTTCCTTCCGGCTGTCGGGATCCAGGATGAGGGGATTTTCCGGTGCCAGGCAATGAACAGGAATGGAAAGGAGACCAAGTCCAACTACCGAGTCCGTGTCTACCAGATTCCTGGGAAGCCAGAAATTGTAGATTCTGCCTCTGAACTCACGGCTGGTGTTCCCAATAAGGTGGGGACATGTGTGTCAGAGGGAAGCTACCCTGCAGGGACTCTTAGCTGGCACTTGGATGGGAAGCCCCTGGTGCCTAATGAGAAGGGAGTATCTGTGAAGGAACAGACCAGGAGACACCCTGAGACAGGGCTCTTCACACTGCAGTCGGAGCTAATGGTGACCCCAGCCCGGGGAGGAGATCCCCGTCCCACCTTCTCCTGTAGCTTCAGCCCAGGCCTTCCCCGACACCGGGCCTTGCGCACAGCCCCCATCCAGCCCCGTGTCTGGGAGCCTGTGCCTCTGGAGGAGGTCCAATTGGTGGTGGAGCCAGAAGGTGGAGCAGTAGCTCCTGGTGGAACCGTAACCCTGACCTGTGAAGTCCCTGCCCAGCCCTCTCCTCAAATCCACTGGATGAAGGATGGTGTGCCCTTGCCCCTTCCCCCCAGCCCTGTGCTGATCCTCCCTGAGATAGGGCCTCAGGACCAGGGAACCTACAGCTGTGTGGCCACCCATTCCAGCCACGGGCCCCAGGAAAGCCGTGCTGTCAGCATCAGCATCATCGAACCAGGCGAGGAGGGGCCAACTGCAGGCTCTGTGGGAGGATCAGGGCTGGGAACTCTAGCCCTGGCCCTGGGGATCCTGGGAGGCCTGGGGACAGCCGCCCTGCTCATTGGGGTCATCTTGTGGCAAAGGCGGCAACGCCGAGGAGAGGAGAGGAAGGCCCCAGAAAACCAGGAGGAAGAGGAGGAGCGTGCAGAACTGAATCAGTCGGAGGAACCTGAGGCAGGCGAGAGTAGTACTGGAGGGCCTTGAGGGGCCCACAGACAGATCCCATCCATCAGCTCCCTTTTCTTTTTCCCTTGAACTGTTCTGGCCTCAGACCAACTCTCTCCTGTATAATCTCTCTCCTGTATAACCCCACCTTGCCAAGCTTTCTTCTACAACCAGAGCCCCCCACAATGATGATTAAACACCTGACACATCTTGCAAAAAAAAAAAAAAAAAA</DNA_Seq>
  </Molecule_Seq>
  <Tissuelocal_List>
    <TissueLocal>
      <TissueLocal>Endothelial cells</TissueLocal>
    </TissueLocal>
  </Tissuelocal_List>
  <CellLocal_List>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Secreted</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to membrane</CellLocal>
      <Ontology_ID>GO:0016021</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Plasma membrane</CellLocal>
      <Ontology_ID>GO:0005886</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Integral to plasma membrane</CellLocal>
      <Ontology_ID>GO:0005887</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Extracellular region</CellLocal>
      <Ontology_ID>GO:0005576</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Membrane</CellLocal>
      <Ontology_ID>GO:0016020</Ontology_ID>
    </AsdMacromoleculeCelllocal>
    <AsdMacromoleculeCelllocal>
        <CellLocal>Cell membrane</CellLocal>
      <Ontology_ID>SwissProt</Ontology_ID>
    </AsdMacromoleculeCelllocal>
  </CellLocal_List>
  <Gene>
    <Gene_Name>AGER</Gene_Name>
    <Gene_Alias>RAGE</Gene_Alias>
    <Gene_ID>177</Gene_ID>
    <Genbank_ACCN>NM_001136</Genbank_ACCN>
    <Protein_ACCN>NP_001127</Protein_ACCN>
    <HGNC_ID>320</HGNC_ID>
    <Gene_URL>http://www.ncbi.nlm.nih.gov/gene/177</Gene_URL>
    <UCSC_ID>uc010jtv.2</UCSC_ID>
    <EMBL_ID>ENSG00000237405</EMBL_ID>
  </Gene>
  <PPI_List>
    <PPI>
      <Uniprot_ID>P04271</Uniprot_ID>
      <Gene_Name>S100B</Gene_Name>
      <EBI_ID>EBI-458391</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-458391</PPI_EBI_URL>
      <Experiment_Number>5</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P25815</Uniprot_ID>
      <Gene_Name>S100P</Gene_Name>
      <EBI_ID>EBI-743700</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-743700</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P02766</Uniprot_ID>
      <Gene_Name>TTR</Gene_Name>
      <EBI_ID>EBI-711909</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-711909</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P61586</Uniprot_ID>
      <Gene_Name>RHOA</Gene_Name>
      <EBI_ID>EBI-446668</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-446668</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P62993</Uniprot_ID>
      <Gene_Name>GRB2</Gene_Name>
      <EBI_ID>EBI-401755</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-401755</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
    <PPI>
      <Uniprot_ID>P16333</Uniprot_ID>
      <Gene_Name>NCK1</Gene_Name>
      <EBI_ID>EBI-389883</EBI_ID>
      <PPI_EBI_URL>EBI-1646426,EBI-389883</PPI_EBI_URL>
      <Experiment_Number>2</Experiment_Number>
    </PPI>
  </PPI_List>
  <Disease_List>
    <Disease>
      <Disease_Name>Obstructive Lung Disease</Disease_Name>
      <Disease_Detail>Obstructive Lung Disease</Disease_Detail>
      <Disease_DB>OBS006</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/obstructive_lung_disease?search=AGER#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Nephropathy</Disease_Name>
      <Disease_Detail>Diabetic Nephropathy</Disease_Detail>
      <Disease_DB>DBT061</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_nephropathy?search=AGER#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Diabetic Angiopathy</Disease_Name>
      <Disease_Detail>Diabetic Angiopathy</Disease_Detail>
      <Disease_DB>DBT008</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/diabetic_angiopathy?search=AGER#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Leukostasis</Disease_Name>
      <Disease_Detail>Leukostasis</Disease_Detail>
      <Disease_DB>LKS001</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/leukostasis?search=AGER#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Vascular Disease</Disease_Name>
      <Disease_Detail>Vascular Disease</Disease_Detail>
      <Disease_DB>VSC007</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/vascular_disease?search=AGER#related_genes</Disease_URL>
    </Disease>
    <Disease>
      <Disease_Name>Type 2 Diabetes Mellitus</Disease_Name>
      <Disease_Detail>Diabetes Mellitus</Disease_Detail>
      <Disease_DB>TYP009</Disease_DB>
      <Disease_URL>http://www.malacards.org/card/type_2_diabetes_mellitus?search=AGER#related_genes</Disease_URL>
    </Disease>
  </Disease_List>
  <PDB_List>
    <PDB>
      <PDB_Title>Solution Structure of C-terminal RAGE (ctRAGE)</PDB_Title>
      <PDB_ID>2LMB</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2LMB</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Signal transduction in receptor for advanced glycation end products (RAGE): solution structure of C-terminal rage (ctRAGE) and its binding to mDia1.</PubMed_Title>
      <Author>Rai, V., et al.</Author>
      <Journal>J.Biol.Chem.(2012)287:5133-5144</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/22194616?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>Structure of CEL-PEP-RAGE V domain complex</PDB_Title>
      <PDB_ID>2L7U</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2L7U</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Advanced glycation end product recognition by the receptor for AGEs.</PubMed_Title>
      <Author>Xue, J., et al.</Author>
      <Journal>Structure(2011)19:722-732</Journal>
      <PubMed_ID>http://www.ncbi.nlm.nih.gov/pubmed/21565706?dopt=Abstract</PubMed_ID>
    </PDB>
    <PDB>
      <PDB_Title>RAGEC2-S100A13 tetrameric complex</PDB_Title>
      <PDB_ID>2LE9</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2LE9</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Interaction of S100A13 with Receptor for Advanced Glycation End products (RAGE) C2 domain</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Solution Structure of Variable-type Domain of Human Receptor for Advanced Glycation Endproducts</PDB_Title>
      <PDB_ID>2E5E</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2E5E</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution Structure of Variable-type  Domain of Human Receptor for Advanced Glycation Endproducts</PubMed_Title>
    </PDB>
    <PDB>
      <PDB_Title>Solution structure of the third ig-like domain from human Advanced glycosylation end product-specific receptor</PDB_Title>
      <PDB_ID>2ENS</PDB_ID>
      <Resolution>-1.0</Resolution>
      <PDB_URL>http://www.pdb.org/pdb/explore/explore.do?structureId=2ENS</PDB_URL>
      <Has_Ligand>No</Has_Ligand>
      <PubMed_Title>Solution structure of the third ig-like domain from human Advanced glycosylation end product-specific receptor</PubMed_Title>
    </PDB>
  </PDB_List>
  <Create_Date>2013-11-12</Create_Date>
</Organism_Record>